tradingkey.logo

BUZZ-Insmed falls on weak 2025 sales forecast for lead drug

ReutersFeb 20, 2025 2:55 PM

Drugmaker Insmed's INSM.O shares fall 1.6% to $82.45

Co forecasts 2025 revenue of $405 million to $425 million for their drug Arikayce, compared with analysts' expectations of $433 million as per data compiled by LSEG

Co reports Q4 revenue of $104.4 million, higher than analysts' est of $102.8 million, driven by Arikayce which is its only commercial drug

The drug is used for treatment of Mycobacterium avium complex (MAC) lung infections, which commonly affect individuals with weakened immune systems

Co reports Q4 loss of $1.32/share vs analyst est of $1.16/share loss

Stock has tripled in the past 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI